RXDX · Prometheus Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.10M | - | $968.0K | $1.27M | $3.92M | - | $359.0K | $179.0K | $228.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $36.42M | - | $29.08M | $25.92M | $27.93M | - | $17.55M | $4.92M | $4.26M |
| SG&A | $13.39M | - | $10.27M | $9.32M | $8.09M | - | $10.25M | $5.62M | $2.39M |
| Total Operating Expenses | $49.81M | - | $39.35M | $35.24M | $36.02M | - | $7.83M | $19.17M | $6.65M |
| D&A | $233.0K | - | $200.0K | $200.0K | $87.0K | - | $100.0K | $27.0K | $22.0K |
| Operating Income | ($48.70M) | - | ($38.38M) | ($33.97M) | ($32.10M) | - | ($7.47M) | ($18.85M) | ($6.42M) |
| Interest Expense | - | - | - | - | - | - | $13.0K | $190.0K | $534.0K |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($40.88M) | - | ($37.27M) | ($33.65M) | ($32.07M) | - | ($6.95M) | ($8.44M) | ($13.13M) |
| EPS - Basic | ($0.82) | - | ($0.90) | ($0.86) | - | - | ($4.55) | ($0.49) | ($9.56) |
| EPS - Diluted | ($0.86) | - | ($0.90) | ($0.86) | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $113.34M | $292.42M | $78.41M | $95.96M | $227.03M | $257.25M | $279.12M | $304.39M | $54.20M |
| Accounts Receivable | - | $1.03M | $941.0K | $1.86M | $1.29M | $1.08M | $679.0K | $217.0K | $973.0K |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.16M | $762.0K | $1.08M | $462.0K | $1.81M | $1.15M | $1.66M | $2.25M | $2.08M |
| Current Assets | $726.40M | $708.15M | $266.06M | $219.35M | $234.98M | $265.38M | $287.11M | $311.59M | $57.46M |
| Total Assets | $758.41M | $740.77M | $298.62M | $237.59M | $253.58M | $267.80M | $288.94M | $313.17M | $59.63M |
| Current Liabilities | $19.34M | $22.82M | $23.78M | $16.47M | $17.32M | $16.44M | $15.09M | $17.70M | $15.26M |
| Long-term Debt | - | - | - | - | - | - | - | $7.40M | $7.40M |
| Total Liabilities | $60.80M | $64.81M | $66.08M | $45.76M | $46.86M | $32.65M | $26.84M | $30.74M | $31.15M |
| Stockholders' Equity | $697.62M | $675.97M | $232.53M | $191.83M | $206.72M | $235.16M | $262.10M | ($58.16M) | $300.20M |
| Retained Earnings | ($371.97M) | ($331.09M) | ($292.33M) | ($255.05M) | ($221.41M) | ($189.34M) | ($159.42M) | ($132.09M) | ($99.15M) |
Cash Flow
| Line item | Q3 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($39.54M) | - | - | - | ($29.39M) | - | - | - | ($5.26M) |
| Investing Cash Flow | ($192.33M) | - | - | - | ($955.0K) | - | - | - | ($1.05M) |
| Financing Cash Flow | $52.80M | - | - | - | $123.0K | - | - | - | $35.31M |
| CapEx | $530.0K | - | - | - | $955.0K | - | - | - | $171.0K |
| Free Cash Flow | ($40.07M) | - | - | - | ($30.34M) | - | - | - | ($5.43M) |
Ratios
| Metric | Q3 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | -4407.6% | - | -3965.2% | -2676.8% | -819.0% | - | -2079.7% | -10528.5% | -2817.5% |
| EBITDA margin | -4386.5% | - | -3944.5% | -2661.0% | -816.8% | - | -2051.8% | -10513.4% | -2807.9% |
| Net margin | -3699.2% | - | -3850.7% | -2651.5% | -818.2% | - | -1935.1% | -4715.1% | -5757.9% |
| Free cash flow margin | -3626.6% | - | - | - | -774.3% | - | - | - | -2381.6% |
| FCF / Net income | 0.98 | - | - | - | 0.95 | - | - | - | 0.41 |
| R&D / Revenue | 3295.7% | - | 3004.0% | 2042.4% | 712.7% | - | 4888.9% | 2750.3% | 1870.6% |
| SG&A / Revenue | 1211.9% | - | 1061.2% | 734.4% | 206.3% | - | 2854.6% | 3138.5% | 1046.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.4% | - | -12.5% | -14.2% | -12.6% | - | -2.4% | -2.7% | -22.0% |
| Return on equity | -5.9% | - | -16.0% | -17.5% | -15.5% | - | -2.7% | 14.5% | -4.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 37.56 | 31.04 | 11.19 | 13.32 | 13.56 | 16.14 | 19.02 | 17.61 | 3.77 |
| Quick ratio | 37.56 | 31.04 | 11.19 | 13.32 | 13.56 | 16.14 | 19.02 | 17.61 | 3.77 |
| Cash ratio | 5.86 | 12.82 | 3.30 | 5.83 | 13.11 | 15.65 | 18.49 | 17.20 | 3.55 |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | -0.13 | 0.02 |
| Debt / Assets | - | - | - | - | - | - | - | 0.02 | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | -574.3x | -99.2x | -12.0x |
| Equity multiplier | 1.09 | 1.10 | 1.28 | 1.24 | 1.23 | 1.14 | 1.10 | -5.38 | 0.20 |
| Liabilities / Assets | 0.08 | 0.09 | 0.22 | 0.19 | 0.18 | 0.12 | 0.09 | 0.10 | 0.52 |
| Efficiency | |||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.02 | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 355d | 536d | 120d | - | 690d | 442d | 1558d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | 14.2% | - | 169.6% | 608.9% | 1618.9% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -26.9% | - | -414.1% | -80.2% | -399.6% | - | - | - | - |
| Net income growth (YoY) | -9.7% | - | -436.6% | -298.7% | -144.3% | - | - | - | - |
| EPS growth (YoY) | 4.4% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -458.8% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 200.0% | 187.5% | -11.3% | - | -31.1% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Prometheus Biosciences against the 5 most active filers in the same SIC group.